Fujirebio/CanAg combination
This article was originally published in The Gray Sheet
Executive Summary
Fujirebio Diagnostics highlights R&D synergies for cancer diagnostics development in acquiring Swedish diagnostics firm CanAg May 31. "The combination...allows us to leverage the technical and scientific resources of both organizations to more effectively and efficiently develop new, innovative assays in the field of cancer care," Fujirebio says. The merger also expands the market platform for CanAg's existing product portfolio...